Therefore, nilotinib is an oral, low-dose (200 mg) therapy that may prevent the accumulation of amyloid and tau, protect blood vessel fibrosis, and prevent inflammation in the spectrum of dementia and cognitive decline. Here, MAPT is linked to Mental deterioration.